Board of Directors of the Moroccan Agency for Medicines Discusses Market Monitoring and Enhancing Proactive Oversight
The second session of the Board of Directors of the Moroccan Agency for Medicines and Health Products was held yesterday in Rabat, chaired by the Minister of Health and Social Protection, Amin Tehraoui. The meeting focused on several strategic issues related to drug market monitoring, enhancing proactive oversight mechanisms, and ensuring coordination with various stakeholders to swiftly address any potential imbalances in supply chains.
During this session, the agency presented its achievements for the year 2025, along with the annual management report, the work program for 2026, forecasts for the period from 2026 to 2028, and the proposed budget for the upcoming year. The board also discussed the establishment of an internal audit committee as part of its commitment to good governance principles and transparency, in addition to addressing various organizational issues aimed at strengthening the agency’s institutional and logistical capacities.
In his speech, the Minister of Health and Social Protection emphasized that this meeting continues the efforts of the agency’s first board meeting, which laid the groundwork for activating its tasks and establishing its governance system. He highlighted the agency’s strategic role in ensuring the quality, safety, and availability of medicines and health products, contributing to strengthening the country’s health sovereignty and instilling public confidence in the health system.
The minister pointed out that this dynamic aligns with the high royal vision aimed at strengthening health sovereignty, ensuring equitable and sustainable access to medicines and health products, supporting high-quality local production, and enhancing national health security.
Regarding the prospects for 2026, Tehraoui explained that the focus will be on capitalizing on achievements, improving the efficiency of processes, accelerating the digitalization initiative, and gradually engaging in regionalized services, as well as enhancing alignment with internationally accepted standards in this field.
For his part, Samir Ahid, Director of the Moroccan Agency for Medicines and Health Products, confirmed that the meeting provided an opportunity to review the progress made in implementing the structural projects for 2025, particularly in the areas of governance and pharmaceutical sector organization, noting that these efforts have yielded positive results in streamlining processes and supporting various actors and stakeholders in the sector.
He added that the council’s discussions also centered on examining the strategic priorities for 2026, with the aim of increasing the agency’s operational pace and enhancing its capabilities, in line with royal directives aimed at strengthening the health system and reinforcing health and pharmaceutical sovereignty.
The Moroccan Agency for Medicines and Health Products has pivotal responsibilities, including ensuring the availability, quality, and safety of medicines and health products, monitoring their prices, and enhancing vigilance and risk analysis, thereby contributing to market stability and improving the effectiveness of public intervention.
